// App-Quantinova.ai

5021 : A randomized phase II study of pelareorep (REO) plus docetaxel vs. docetaxel alone in patients with metastatic castration resistant prostate cancer (mCRPC): Canadian Cancer Trials Group study IND 209.

Researchers

Presenter

  • Bernhard J. Eigl

Principal Investigators

  • Eric Winquist

  • Dongsheng Tu

  • Sebastien J. Hotte

  • Christina M. Canil

  • Richard William Gregg

  • Muhammad Zulfiqar

  • Scott A. North

  • Susan Ellard

  • Joseph D. Ruether

  • Lyly H. Le

  • Ankineedu Saranya Kakumanu

  • Ashley Theis

  • Christopher M. Booth

  • Kylea R. Potvin

  • Kim N. Chi

  • Lesley Seymour

Medical Centers

  • BC Cancer Agency, Vancouver, BC, Canada

  • London Health Sciences Center, London, ON, Canada

  • Canadian Cancer Trials Group, Kingston, ON, Canada

  • Escarpment Cancer Research Institute, Juravinski Cancer Centre, Hamilton, ON, Canada

  • Ottawa Regional Cancer Centre, Manotick, ON, Canada

  • Cancer Centre Of Southeastern Ontario, Kingston, ON, Canada

  • BC Cancer Agency, Abbotsford, BC, Canada

  • Cross Cancer Institute, Edmonton, AB, Canada

  • BCCA, Kelowna, BC, Canada

  • Tom Baker Cancer Center, Calgary, AB, Canada

  • BC Cancer Agency, Surrey, BC, Canada

  • Allan Blair Cancer Ctr, Regina, SK, Canada

  • Division of Cancer Care & Epidemiology, Cancer Research Institute, Queen's University, Kingston, ON, Canada

  • University of Western Ontario, London, ON, Canada

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Queen's University, Kingston, ON, CA

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • Pelareorep

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • NCT01619813

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved